Read More

Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan

JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the ongoing launch of Elahere (mirvetuximab soravtansine-gynx) in platinum-resistant

IMGN